Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Presentation

Zinc Finger Protein Transcription Factors Targeting Alpha-synuclein – A Promising Therapeutic Strategy for Parkinson’s Disease

Download PDF